BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Voisin T, El Firar A, Fasseu M, Rouyer-Fessard C, Descatoire V, Walker F, Paradis V, Bedossa P, Henin D, Lehy T, Laburthe M. Aberrant expression of OX1 receptors for orexins in colon cancers and liver metastases: an openable gate to apoptosis. Cancer Res 2011;71:3341-51. [PMID: 21415167 DOI: 10.1158/0008-5472.CAN-10-3473] [Cited by in Crossref: 53] [Cited by in F6Publishing: 25] [Article Influence: 4.8] [Reference Citation Analysis]
Number Citing Articles
1 Couvineau A, Dayot S, Nicole P, Gratio V, Rebours V, Couvelard A, Voisin T. The Anti-tumoral Properties of Orexin/Hypocretin Hypothalamic Neuropeptides: An Unexpected Therapeutic Role. Front Endocrinol (Lausanne) 2018;9:573. [PMID: 30319552 DOI: 10.3389/fendo.2018.00573] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
2 Graybill NL, Weissig V. A review of orexin's unprecedented potential as a novel, highly-specific treatment for various localized and metastatic cancers. SAGE Open Med 2017;5:2050312117735774. [PMID: 29147564 DOI: 10.1177/2050312117735774] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.6] [Reference Citation Analysis]
3 Couvineau A, Voisin T, Nicole P, Gratio V, Abad C, Tan YV. Orexins as Novel Therapeutic Targets in Inflammatory and Neurodegenerative Diseases. Front Endocrinol (Lausanne) 2019;10:709. [PMID: 31695678 DOI: 10.3389/fendo.2019.00709] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 4.3] [Reference Citation Analysis]
4 Dayot S, Speisky D, Couvelard A, Bourgoin P, Gratio V, Cros J, Rebours V, Sauvanet A, Bedossa P, Paradis V, Ruszniewski P, Couvineau A, Voisin T. In vitro, in vivo and ex vivo demonstration of the antitumoral role of hypocretin-1/orexin-A and almorexant in pancreatic ductal adenocarcinoma. Oncotarget 2018;9:6952-67. [PMID: 29467942 DOI: 10.18632/oncotarget.24084] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
5 Biegańska K, Sokołowska P, Jöhren O, Zawilska JB. Orexin A suppresses the growth of rat C6 glioma cells via a caspase-dependent mechanism. J Mol Neurosci 2012;48:706-12. [PMID: 22588980 DOI: 10.1007/s12031-012-9799-0] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 2.1] [Reference Citation Analysis]
6 Mogavero MP, Silvani A, DelRosso LM, Salemi M, Ferri R. Focus on the Complex Interconnection between Cancer, Narcolepsy and Other Neurodegenerative Diseases: A Possible Case of Orexin-Dependent Inverse Comorbidity. Cancers (Basel) 2021;13:2612. [PMID: 34073579 DOI: 10.3390/cancers13112612] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
7 Kukkonen JP, Leonard CS. Orexin/hypocretin receptor signalling cascades. Br J Pharmacol 2014;171:314-31. [PMID: 23902572 DOI: 10.1111/bph.12324] [Cited by in Crossref: 104] [Cited by in F6Publishing: 91] [Article Influence: 13.0] [Reference Citation Analysis]
8 Leonard CS, Kukkonen JP. Orexin/hypocretin receptor signalling: a functional perspective. Br J Pharmacol 2014;171:294-313. [PMID: 23848055 DOI: 10.1111/bph.12296] [Cited by in Crossref: 82] [Cited by in F6Publishing: 84] [Article Influence: 10.3] [Reference Citation Analysis]
9 Lappano R, Maggiolini M. GPCRs and cancer. Acta Pharmacol Sin 2012;33:351-62. [PMID: 22266725 DOI: 10.1038/aps.2011.183] [Cited by in Crossref: 58] [Cited by in F6Publishing: 51] [Article Influence: 5.8] [Reference Citation Analysis]
10 Blais A, Drouin G, Chaumontet C, Voisin T, Couvelard A, Even PC, Couvineau A. Impact of Orexin-A Treatment on Food Intake, Energy Metabolism and Body Weight in Mice. PLoS One 2017;12:e0169908. [PMID: 28085909 DOI: 10.1371/journal.pone.0169908] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 3.2] [Reference Citation Analysis]
11 Couvineau A, Voisin T, Nicole P, Gratio V, Blais A. Orexins: A promising target to digestive cancers, inflammation, obesity and metabolism dysfunctions. World J Gastroenterol 2021; 27(44): 7582-7596 [PMID: 34908800 DOI: 10.3748/wjg.v27.i44.7582] [Reference Citation Analysis]
12 Chaudhary PK, Kim S. An Insight into GPCR and G-Proteins as Cancer Drivers. Cells 2021;10:3288. [DOI: 10.3390/cells10123288] [Reference Citation Analysis]
13 Wang L, Gu Y, Zhang J, Gong L. Effects of Sleep Deprivation (SD) on Rats via ERK1/2 Signaling Pathway. Med Sci Monit. 2019;25:2886-2895. [PMID: 31002658 DOI: 10.12659/msm.913839] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
14 Huh E, Gallion J, Agosto MA, Wright SJ, Wensel TG, Lichtarge O. Recurrent high-impact mutations at cognate structural positions in class A G protein-coupled receptors expressed in tumors. Proc Natl Acad Sci U S A 2021;118:e2113373118. [PMID: 34916293 DOI: 10.1073/pnas.2113373118] [Reference Citation Analysis]
15 Avelino-Flores Mdel C, Cruz-López Mdel C, Jiménez-Montejo FE, Reyes-Leyva J. Cytotoxic activity of the methanolic extract of Turnera diffusa Willd on breast cancer cells. J Med Food 2015;18:299-305. [PMID: 25299247 DOI: 10.1089/jmf.2013.0055] [Cited by in Crossref: 13] [Cited by in F6Publishing: 6] [Article Influence: 1.6] [Reference Citation Analysis]
16 Zhang YX, Li XF, Yuan GQ, Hu H, Song XY, Li JY, Miao XK, Zhou TX, Yang WL, Zhang XW, Mou LY, Wang R. β-Arrestin 1 has an essential role in neurokinin-1 receptor-mediated glioblastoma cell proliferation and G2/M phase transition. J Biol Chem 2017;292:8933-47. [PMID: 28341744 DOI: 10.1074/jbc.M116.770420] [Cited by in Crossref: 22] [Cited by in F6Publishing: 13] [Article Influence: 4.4] [Reference Citation Analysis]
17 Turku A, Rinne MK, Boije Af Gennäs G, Xhaard H, Lindholm D, Kukkonen JP. Orexin receptor agonist Yan 7874 is a weak agonist of orexin/hypocretin receptors and shows orexin receptor-independent cytotoxicity. PLoS One 2017;12:e0178526. [PMID: 28575023 DOI: 10.1371/journal.pone.0178526] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 2.6] [Reference Citation Analysis]
18 Liguori G, Squillacioti C, Assisi L, Pelagalli A, Vittoria A, Costagliola A, Mirabella N. Potential role of orexin A binding the receptor 1 for orexins in normal and cryptorchid dogs. BMC Vet Res 2018;14:55. [PMID: 29482574 DOI: 10.1186/s12917-018-1375-6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
19 Ward RJ, Pediani JD, Milligan G. Heteromultimerization of cannabinoid CB(1) receptor and orexin OX(1) receptor generates a unique complex in which both protomers are regulated by orexin A. J Biol Chem 2011;286:37414-28. [PMID: 21908614 DOI: 10.1074/jbc.M111.287649] [Cited by in Crossref: 64] [Cited by in F6Publishing: 30] [Article Influence: 5.8] [Reference Citation Analysis]
20 Wen J, Chang X, Bai B, Gao Q, Zhao Y. Orexin A Suppresses the Expression of Exosomal PD-L1 in Colon Cancer and Promotes T Cell Activity by Inhibiting JAK2/STAT3 Signaling Pathway. Dig Dis Sci 2021. [PMID: 34097168 DOI: 10.1007/s10620-021-07077-0] [Reference Citation Analysis]
21 Laburthe M. [How to turn a silent proapoptotic gene in a potent antitumoral target in colorectal cancer]. Med Sci (Paris) 2012;28:272-3. [PMID: 22480651 DOI: 10.1051/medsci/2012283015] [Reference Citation Analysis]
22 Wang CM, Yang CQ, Cheng BH, Chen J, Bai B. Orexin-A protects SH-SY5Y cells against H2O2-induced oxidative damage via the PI3K/MEK1/2/ERK1/2 signaling pathway. Int J Immunopathol Pharmacol 2018;32:2058738418785739. [PMID: 29983082 DOI: 10.1177/2058738418785739] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 3.3] [Reference Citation Analysis]
23 Misawa K, Imai A, Mochizuki D, Misawa Y, Endo S, Hosokawa S, Ishikawa R, Mima M, Shinmura K, Kanazawa T, Mineta H. Genes encoding neuropeptide receptors are epigenetic markers in patients with head and neck cancer: a site-specific analysis. Oncotarget 2017;8:76318-28. [PMID: 29100314 DOI: 10.18632/oncotarget.19356] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.2] [Reference Citation Analysis]
24 Alain C, Pascal N, Valérie G, Thierry V. Orexins/Hypocretins and Cancer: A Neuropeptide as Emerging Target. Molecules 2021;26:4849. [PMID: 34443437 DOI: 10.3390/molecules26164849] [Reference Citation Analysis]
25 Laburthe M, Voisin T. The orexin receptor OX(1)R in colon cancer: a promising therapeutic target and a new paradigm in G protein-coupled receptor signalling through ITIMs. Br J Pharmacol 2012;165:1678-87. [PMID: 21627633 DOI: 10.1111/j.1476-5381.2011.01510.x] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 2.3] [Reference Citation Analysis]
26 Nicole P, Couvineau P, Jamin N, Voisin T, Couvineau A. Crucial role of the orexin-B C-terminus in the induction of OX1 receptor-mediated apoptosis: analysis by alanine scanning, molecular modelling and site-directed mutagenesis. Br J Pharmacol 2015;172:5211-23. [PMID: 26282891 DOI: 10.1111/bph.13287] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
27 Wan X, Liu Y, Zhao Y, Sun X, Fan D, Guo L. Orexin A affects HepG2 human hepatocellular carcinoma cells glucose metabolism via HIF-1α-dependent and -independent mechanism. PLoS One 2017;12:e0184213. [PMID: 28886081 DOI: 10.1371/journal.pone.0184213] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
28 Tunisi L, Forte N, Fernández-Rilo AC, Mavaro I, Capasso R, D'Angelo L, Milić N, Cristino L, Di Marzo V, Palomba L. Orexin-A Prevents Lipopolysaccharide-Induced Neuroinflammation at the Level of the Intestinal Barrier. Front Endocrinol (Lausanne) 2019;10:219. [PMID: 31024456 DOI: 10.3389/fendo.2019.00219] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]